Work

P2.06-07 PD-L1 Expression Guidance on Sintilimab versus Pembrolizumab in Untreated Advanced NSCLC (CTONG1901)

Year: 2023

Type: article

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2023.09.553

Authors: S.-Y.M. Liu, J.-Y. Deng, H.-H. Yan, M.-Y. Yang, C.-R. Xu, M.-Y. Zheng, B. Gan, X.-C. Zhang, H.-Y. Tu, J.-J. Yang, H.-J. Chen, B.-C. Wang, Y. Li, Q. Zhou, Y.-L. Wu

Institutions: Jinan University, First Affiliated Hospital of Jinan University, Guangdong Academy of Medical Sciences, Guangdong Provincial People's Hospital, Southern Medical University

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4388045965

FWCI:

Cites:

Cited by:

Related to: 10